Gustavo Noriz Berardinelli

Gustavo Noriz Berardinelli

Auto-generated profile, based on publicly available information

Gustavo Noriz Berardinelli

Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Pharmacological Research
Verified
Journal Article
Closed access
SSSilvana Sandri
Silvana Sandri
FFFernanda Faião-Flores
Fernanda Faião-Flores
MTManoela Tiago
Manoela Tiago
PPPaula Comune Pennacchi
Paula Comune Pennacchi
RMRenato Ramos Massaro
Renato Ramos Massaro
SMSilvya Maria-Engler
Silvya Maria-Engler

5 May 2020 in Pathobiology
Verified
Journal Article
Open access
NCNathália C. Campanella
Nathália C. Campanella
ESEduardo Caetano Silva
Eduardo Caetano Silva
GDGustavo Dix
Gustavo Dix
FVFabiana Lima Vazquez
Fabiana Lima Vazquez
FPFlávia Escremim de Paula
Flávia Escremim de Paula
RRRui M. Reis
Rui M. Reis
Background: Malignant pleural mesothelioma (MPM) is a highly lethal disease comprising a heterogeneous group of tumors with challenging to predict biological behavior. The diagnosis is complex, and the histologic classification includes 2 major subtypes of MPM: epithelioid (∼60% of cases) and sarcomatous (∼20%). Its identification depends upon pathological investigation supported by clinical and radiological evidence and more recently ancillary molecular testing. Treatment options are currently limited, with no known targeted therapies available. Objectives: To elucidate the mutation profile of driver tumor suppressor and oncogenic genes in a cohort of Brazilian patients. Methods: We sequenced 16 driver genes in a series of 43 Brazilian malignant mesothelioma (MM) patients from 3 distinct Brazilian centers. Genomic DNA was extracted from formalin-fixed paraffin-embedded tumor tissue blocks, and the TERT promoter region was amplified by PCR followed by direct capillary sequencing. The Illumina TruSight Tumor 15 was used to evaluate 250 amplicons from 15 genes associated with solid tumors (AKT1, GNA11, NRAS, BRAF, GNAQ, PDGFRA, EGFR, KIT, PIK3CA, ERBB2, KRAS, RET, FOXL2, MET,and TP53). Library preparation with the TruSight Tumor 15 was performed before sequencing at the MiSeq platform. Data analysis was performed using Sophia DDM software. Results: Out of 43 MPM patients, 38 (88.4%) were epithelioid subtype and 5 (11.6%) were sarcomatoid histotype. Asbestos exposure was present in 15 (39.5%) patients with epithelioid MPM and 3 (60%) patients with sarcomatoid MPM. We found a TERT promoter mutation in 11.6% of MM, and the c.-146C>T mutation was the most common event. The next-generation sequencing was successful in 33 cases. A total of 18 samples showed at least 1 pathogenic, with a median of 1.8 variants, ranging from 1 to 6. The most mutated genes were TP53 and ERBB2 with 7 variants each, followed by NRAS BRAF, PI3KCA, EGFR and PDGFRA with 2 variants each. KIT, AKT1, and FOXL2 genes exhibited 1 variant each. Interestingly, 2 variants observed in the PDGFRA gene are classic imatinib-sensitive therapy. Conclusions: We concluded that Brazilian MPM harbor mutation in classic tumor suppressor and oncogenic genes, which might help in the guidance of personalized treatment of MPM.

8 April 2023 in Pathobiology
Verified
Journal Article
Closed access
PDF file
RCRodrigo de Oliveira Cavagna
Rodrigo de Oliveira Cavagna
IPIcaro Alves Pinto
Icaro Alves Pinto
FPFlávia Escremim de Paula
Flávia Escremim de Paula
GBGustavo Noriz Berardinelli
Gustavo Noriz Berardinelli
DSDébora Sant'ANna
Débora Sant'ANna
RRRui M. Reis
Rui M. Reis
Introduction: TP53 is the most frequently mutated gene in lung tumors, but its prognostic role in admixed populations, such as Brazilians, remains unclear. In this study, we aimed to evaluate the frequency and clinicopathological impact of TP53 mutations in non-small cell lung cancer (NSCLC) patients in Brazil. Methods: We analyzed 446 NSCLC patients from Barretos Cancer Hospital. TP53 mutational status was evaluated through targeted next-generation sequencing (NGS) and the variants were biologically classified as disruptive/nondisruptive and as truncating/nontruncating. We also assessed genetic ancestry using 46 ancestry-informative markers. Analysis of lung adenocarcinomas from the cBioportal dataset was performed. We further examined associations of TP53 mutations with patients’ clinicopathological features. Results: TP53 mutations were detected in 64.3% (n = 287/446) of NSCLC cases, with a prevalence of 60.4% (n = 221/366) in lung adenocarcinomas. TP53 mutations were associated with brain metastasis at diagnosis, tobacco consumption, and higher African ancestry. Disruptive and truncating mutations were associated with a younger age at diagnosis. Additionally, cBioportal dataset revealed that TP53 mutations were associated with younger age and Black skin color. Patients harboring disruptive/truncating TP53 mutations had worse overall survival than nondisruptive/nontruncating and wild-type patients. Conclusion: TP53 mutations are common in Brazilian lung adenocarcinomas, and their biological characterization as disruptive and truncating mutations is associated with African ancestry and shorter overall survival.

1 December 2018 in Cancer Genetics
Verified
Journal Article
Closed access
PFPaula Felicio
Paula Felicio
BABarbara Alemar
Barbara Alemar
ACAline Silva Coelho
Aline Silva Coelho
GBGustavo Noriz Berardinelli
Gustavo Noriz Berardinelli
MMMatias Eliseo Melendez
Matias Eliseo Melendez
EPEdenir Palmero
Edenir Palmero

5 June 2024 in Translational Oncology
Verified
Journal Article
Open access
LZLuis Eduardo Rosa Zucca
Luis Eduardo Rosa Zucca
ALAna Carolina Laus
Ana Carolina Laus
BSBruna Sorroche
Bruna Sorroche
EPEduarda Paro
Eduarda Paro
LSLuciane Sussuchi da Silva
Luciane Sussuchi da Silva
FCFlavio Carcano
Flavio Carcano
One-hundred-six patients diagnosed with non-muscle invasive bladder cancer and treated with intravesical BCG were included and divided into two groups, BCG-responsive (n = 47) and -unresponsive (n = 59). Immunohistochemistry was used to evaluate PD-L1 expression and MSI was assessed by a commercial multiplex PCR kit. The mRNA expression profile of 15 immune checkpoints was performed using the nCounter technology. For in silico validation, two distinct cohorts sourced from the Gene Expression Omnibus (GEO) database were used. Among the 106 patients, only one (<1 %) exhibited MSI instability. PD-L1 expression was present in 9.4 % of cases, and no association was found with BCG-responsive status. We found low gene expression of canonic actionable immune checkpoints PDCD1 (PD-1), CD274 (PD-L1), and CTLA4, while high expression was observed for CD276 (B7-H3), CD47, TNFRSF14, IDO1 and PVR (CD155) genes. High IDO1 expression levels was associated with worst overall survival. The PDCD1, CTLA4 and TNFRSF14 expression levels were associated with BCG responsiveness, whereas TIGIT and CD276 were associated with unresponsiveness. Finally, CD276 was validated in silico cohorts. In NMIBC, MSI is rare and PD-L1 expression is present in a small subset of cases. Expression levels of PDCD1, CTLA4, TNFRSF14, TIGIT and CD276 could constitute predictive biomarkers of BCG responsiveness.

1 February 2023 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
FGFelipe Antonio de Oliveira Garcia
Felipe Antonio de Oliveira Garcia
AEAdriane Evangelista
Adriane Evangelista
BMBRUNA MINNITI MANÇANO
BRUNA MINNITI MANÇANO
DMDaniel Antunes Moreno
Daniel Antunes Moreno
GBGustavo Noriz Berardinelli
Gustavo Noriz Berardinelli
RRRui M. Reis
Rui M. Reis
Choroid plexus tumors (CPTs) are rare intracranial neoplasms, representing <1% of all brain tumors, yet they represent 20% of first-year pediatric brain tumors. Although these tumors have been linked toTP53germline mutations in the context of Li–Fraumeni syndrome, their somatic driver alterations remain poorly understood. In this study, we report two cases of lateral ventricle tumors: 3-yr-old male diagnosed with an atypical choroid plexus papilloma (aCPP), and a 6-mo-old female diagnosed with a choroid plexus carcinoma (CPC). We performed whole-exome sequencing of paired blood and tumor tissue in both patients, categorized somatic variants, and determined copy-number alterations. Our analysis revealed a tier II variant (Association for Molecular Pathology [AMP] criteria) inBRD1,aH3andTP53acetylation agent, in the aCPP. In addition, we detected copy-number gains on Chromosomes 12, 18, and 20 and copy-number losses on Chromosomes 13q and 22q (BRD1locus) in this tumor. The CPC tumor had only a pathogenic germlineTP53variant, based on American College of Medical Genetics (ACMG) criteria, with a clinical and familiar history of Li–Fraumeni syndrome. The CPC patient presented loss of heterozygosity (LoH) ofTP53loci and hyperdiploid genome. Both tumors were microsatellite-stable. This is the first study performing whole-exome sequencing in Brazilian choroid plexus tumors, and in line with the literature, we corroborate the absence of recurrent somatic mutations in these tumors. Further studies with larger sample sizes are necessary to confirm our findings and better understand the underlying biology of these tumors.